Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 2, 2024
Data Byte
FDA approved five NMEs in April
Day One, X4 and ImmunityBio each received their first drug approvals
BioCentury | Mar 28, 2024
Data Byte
Eight PDUFA dates on deck in April
J&J and Legend’s CAR T therapy could move into earlier lines; Day One could get its first marketed product
BioCentury | Mar 26, 2024
Distillery Therapeutics
ASO enhancing vascular cell CXCR4 expression for atherosclerosis
BioCentury | Oct 31, 2023
Deals
Oct. 31 Quick Takes: Lilly buying Beam’s opt-in rights for Verve base editing programs
Plus: GSK buys Janssen’s rights to Arrowhead HBV product and more from Galapagos, Sarepta, Amgen, LianBio and X4
BioCentury | Oct 18, 2023
Data Byte
FDA’s NME approvals in September
Agency approved two new cancer and one new neuro drug; plus Amicus’ Pompe therapy among pair of approvals for rare metabolic disorders
BioCentury | Sep 6, 2023
Data Byte
11 PDUFA dates on FDA’s agenda in September
Decisions due this month include BioLineRx’s Aphexda, Roche’s subcutaneous Tecentriq and GSK’s momelotinib
BioCentury | Jul 18, 2023
Distillery Therapeutics
Bispecific anti-CD206 and CXCR4 glycopeptide for postoperative bladder cancer
BioCentury | Jul 1, 2021
Finance
June 30 Quick Takes: Beam looks to complement Apellis; plus Intellia, Aerovate, Hutchmed, Spero-Pfizer and more
Beam Therapeutics Inc. (NASDAQ:BEAM) unveiled a five-year partnership with Apellis Pharmaceuticals Inc. (NASDAQ:APLS) to collaborate on up to six research programs against complement system targets,
BioCentury | Apr 7, 2021
Distillery Therapeutics
CXCR4 antagonist identified for hepatocellular carcinoma
DISEASE CATEGORY: Cancer
INDICATION: Liver cancer An oxopropylaminoacetic acid-based CXCR4 antagonist could treat hepatocellular carcinoma (HCC). The CXCR4 inhibitor, optimized from a compound
INDICATION: Liver cancer An oxopropylaminoacetic acid-based CXCR4 antagonist could treat hepatocellular carcinoma (HCC). The CXCR4 inhibitor, optimized from a compound
BioCentury | Jul 31, 2020
Finance
Polyphor gains financial cushion ahead of Phase III readout of lone clinical program
Items per page:
1 - 10 of 208